Another study using TCR-tg mice and ACT of tumor-specific CD4+ T cells demonstrated that mouse lymphoma and melanoma were rejected through an IFNγ-dependent mechanism that involved indirect activation of CD4+ T cells by secreted antigen expressed on host APCs (27). The gene discussed is CD4; the disease is melanoma.